Characterization of Brain Metastases

This study has been completed.
Sponsor:
Collaborator:
The Royal Norwegian Ministry of Health
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00184275
First received: September 13, 2005
Last updated: March 6, 2014
Last verified: March 2014
  Purpose

The purpose is to characterize tumour biological markers in brain metastases tissue from patients with different primary tumour by using ex vivo techniques as high-resolution magic angle spinning MR spectroscopy and micro array.


Condition
Neoplasm Metastasis
Lung Neoplasms
Breast Neoplasms
Melanoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Brain Metastases Tissue Characterized by High-resolution Magic Angle Spinning MR and Micro Array

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Biospecimen Retention:   Samples With DNA

frozen tumor tissue samples


Enrollment: 26
Study Start Date: May 2005
Study Completion Date: December 2010
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with brain metastases

Criteria

Inclusion Criteria:

  • Clinical diagnosis of brain metastases

Exclusion Criteria:

  • children
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184275

Locations
Norway
Norwegian University of Science and Technology, Faculty of Medicine
Trondheim, Norway, N-7489
Sponsors and Collaborators
Norwegian University of Science and Technology
The Royal Norwegian Ministry of Health
Investigators
Study Director: Steinar Lundgren, MD PhD Cancer Clinic, St.Olavs Hospital Trondheim University Hospital
Study Chair: Ingrid S Gribbestad, PhD Norwegian University of Science and Technology, Faculty of Medicine
  More Information

Publications:
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00184275     History of Changes
Other Study ID Numbers: 12621
Study First Received: September 13, 2005
Last Updated: March 6, 2014
Health Authority: Norway: Norwegian Social Science Data Services

Keywords provided by Norwegian University of Science and Technology:
Brain metastasis
HR MAS spectroscopy
Tissue micro array
DNA micro array

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms
Lung Neoplasms
Melanoma
Neoplasm Metastasis
Neoplasms, Second Primary
Brain Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on July 26, 2014